Provenge Approved by FDA as the first FDA-approved autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon has created a new website www.provenge.com to provide information to physicians and patients. For information such as ordering, scheduling, tracking, and general coverage and reimbursement questions, contact a Dendreon ON Call specialist at (877) 336-3736.
PCRI first presented the concept of Provenge at a 1997 conference in Seattle moderated by Dr. Stephen Strum. We have covered the development in several Insights articles including:
- Dendritic Cells - Key to PC Immunotherapy, in Oct 2001
- Update on Provenge Trials - Sept 2005,
- Update on Provenge Trials - Nov 2006
- Dendreon Files BLA for Provenge®
PCRI’s Jan Manarite coordinated Raise A Voice, the grass roots initiative for advanced PC awareness and advocacy. Raise a Voice provided patient perspectives at the March 29, 2007 FDA’s CBER committee meeting to review Provenge (sipuleucel-T) and organized a June 4, 2007 rally at the US Capital Building to raise awareness to the needs of patients with advanced prostate cancer.